Stem cell transplantation for ischemic stroke

Boncoraglio, Giorgio B.; Ranieri, Michela; Bersano, Anna; Parati, Eugenio; Giovane, Cinzia Del

doi:10.1002/14651858.cd007231.pub3

Cited by 46 publications

(24 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На платформі Cochrane Library представлено аналіз досліджень «трансплантація СК при ІІ», проведений з використанням ресурсів Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE, Embase, BIOSIS станом на серпень 2018 р. [1]. У попередній огляд 2010 р. було залучено 18 досліджень (фази ІІ-ІІІ) із 3 тис.…”

Section: застосування мезенхімальних стовбурових клітин кісткового моunclassified

“…Жодних значних проблем щодо безпечності такої терапії не виявлено (жодного летального випадку). Однак ці висновки зроблено здебільшого на невеликих вибірках з високим ризиком упередженості, тому потрібно провести більш продумані випробування [1].…”

Section: застосування мезенхімальних стовбурових клітин кісткового моunclassified

“…Інсульт є провідною причиною захворюваності та смертності в світі з дуже великими витратами на охорону здоров'я і соціальну допомогу, що зумовлює потребу в альтернативних терапевтичних підходах [1]. Щороку в світі реєструють близько 13,7 млн нових інсультів.…”

unclassified

See 2 more Smart Citations

Autologous cell using for the restoration of functional defects in patients with ischemic cerebrovascular accident

Pedachenko

Moroz

Yatsyk

et al. 2020

Endovasc. Neurorad.

View full text Add to dashboard Cite

Stroke is a global medical and socio-economic problem and a great demand for alternative therapies, the leading one being stem cell (SC) therapy. Pathogenetic processes in ischemic stroke (II) trigger the mechanisms of necrotic and apoptotic death of neurons with the formation of the central infarct zone («core of ischemia») and the ischemic «penumbra» zone; the severity and reversibility of the injury directly depends on the duration of ischemia. In parallel with pathogenetic processes, endogenous neurogenesis occurs – the proliferation of neurogenic stem and progenitor cells (NSC/NPC) and their migration into the ischemic focus; however, most NSCs and newly formed neurons undergo apoptosis and recovery of lost functions does not occur. Significant efforts are being made to find ways to control neurogenesis, in particular through the transplantation of exogenous SCs. The main factors preventing the use of SCs in humans are moral, ethical, religious and legal aspects related to the source and method of obtaining cells, as well as possible immunocompromised complications due to incompatibility of donor cells with the recipient of the main histocompatibility complex antigens. The safest is the use of autologous SCs (the patient’s own cells), as it does not require the use of immunosuppressive protocols. Due to the relative safety and ease of production, the most common are multipotent mesenchymal stem cells (MSCs), namely MSCs of the bone marrow (BM). Numerous preclinical studies in experimental animals with modeled II, as well as clinical trials conducted over the past 15 years, have shown the safety and feasibility of transplantation of autologous MSCs in patients with severe neurological deficits after II. Two different approaches to the use of MSCs are discussed: neuroprotection in the acute phase and neurorestoration in the chronic phase II. Proposals are currently being developed for phase II/III clinical trials in acute and chronic stroke using BM MSCs, the results of which will form the basis for certified standardized II treatment protocols.

show abstract

Section: застосування мезенхімальних стовбурових клітин кісткового моunclassified

unclassified

See 1 more Smart Citation

Autologous cell using for the restoration of functional defects in patients with ischemic cerebrovascular accident

Pedachenko

Moroz

Yatsyk

et al. 2020

Endovasc. Neurorad.

View full text Add to dashboard Cite

show abstract

“…The use of stem cells as a convalescent therapy after stroke has been established in animal models and is now transferred as a promising tool in human trials (94,95). A 2019 Cochrane database analysis of randomized clinical trials of stem cell transplantation for ischemic stroke suggested an improvement in clinical outcome in patients (96). Nevertheless, the authors of the study concluded that the evidence base for an accurate assessment of stem cell therapy for the treatment of ischemic stroke is still insufficient, and further research in this field is thus urgently needed.…”

Section: Neuroregenerative Approaches Using Stem Cells and Evsmentioning

confidence: 99%

Treating Cerebral Ischemia: Novel Therapeutic Strategies from Experimental Stroke Research

et al. 2021

View full text Add to dashboard Cite

Although systemic thrombolysis and endovascular treatment have revolutionized modern stroke treatment, the majority of patients do not qualify for either treatment paradigm. Hence, novel adjuvant therapeutic strategies are required. This chapter provides an overview of our current understanding of novel therapeutic strategies in preclinical stroke models. The chapter is organized in three major parts to cover the acute, subacute, and chronic phases of ischemic stroke. The potential of various pharmacological agents, stem cells, microRNAs, and extracellular vesicles as therapeutic avenues along with the progress and challenges are discussed.

show abstract

“…Previous preclinical researches have shown that stem cell transplantation could lead to functional improvement of ischemic stroke animal models (Wei et al, 2017;Boncoraglio et al, 2019). The stem cells involved in these studies included neural stem cells (NSCs; Boese et al, 2018), mesenchymal stem cells (MSCs; Kranz et al, 2010;Oshita et al, 2020), induced pluripotent stem cells (iPSCs; Gervois et al, 2016), and so on.…”

Section: Introductionmentioning

confidence: 99%

Olfactory Mucosa Mesenchymal Stem Cells Alleviate Cerebral Ischemia/Reperfusion Injury Via Golgi Apparatus Secretory Pathway Ca2+ -ATPase Isoform1

Liu

Huang

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Olfactory mucosa mesenchymal stem cells (OM-MSCs) have exhibited their effectiveness in central nervous system diseases and provided an appealing candidate for the treatment of ischemic stroke. Previous evidence have shown that Golgi apparatus (GA) secretory pathway Ca 2+ -ATPase isoform1 (SPCA1) was a potential therapeutic target for ischemic stroke. In this study, we explored the neuroprotective mechanism of OM-MSCs and its effect on the expression and function of SPCA1 during cerebral ischemia/reperfusion. Based on in vitro and in vivo experiments, we discovered that OM-MSCs attenuated apoptosis and oxidative stress in ischemic stroke models, reduced the cerebral infarction volume, and improved the neurologic deficits of rats. OM-MSCs also upregulated SPCA1 expression and alleviated Ca 2+ overload and decreased the edema and dissolution of the GA in neurons. Moreover, we discovered that SPCA1 depletion in oxygen and glucose deprivation/reoxygenation (OGD/R)-treated N2a cells mitigated the protective effects of OM-MSCs. Altogether, OM-MSCs exerted neuroprotective effects in ischemic stroke probably via modulating SPCA1 and reducing the edema and dissolution of the GA in neurons.

show abstract

Stem cell transplantation for ischemic stroke

Cited by 46 publications

References 61 publications

Autologous cell using for the restoration of functional defects in patients with ischemic cerebrovascular accident

Autologous cell using for the restoration of functional defects in patients with ischemic cerebrovascular accident

Treating Cerebral Ischemia: Novel Therapeutic Strategies from Experimental Stroke Research

Olfactory Mucosa Mesenchymal Stem Cells Alleviate Cerebral Ischemia/Reperfusion Injury Via Golgi Apparatus Secretory Pathway Ca2+ -ATPase Isoform1

Contact Info

Product

Resources

About